Health Rounds: Researchers discover key to the placebo effect in the brain
Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here.
By Nancy Lapid
July 25 (Reuters) -Hello Health Rounds Readers! Today we highlight three early experimental findings: a fascinating discovery that may help explain the placebo effect, which causes people to respond to fake drugs, and two discoveries that could lead to treatments for keeping breast cancer tumors from growing and colon cancer from spreading to the liver.
Scientists find site of placebo effect in brain
Neuroscientists have discovered a key piece of a puzzle to explain the placebo effect in which individuals appear to respond and feel better after receiving a fake pill or treatment, according to a report published on Wednesday in Nature.
Studying mice, the researchers found that when the animals are expecting pain relief, neurons and synapses along a pain control pathway in the brain are activated even when no medication has been given.
The pathway runs from the cingulate cortex in the front of the brain, through the pons region of the brainstem, to the cerebellum in the back of the brain.
“That neurons in our cerebral cortex communicate with the pons and cerebellum to adjust pain thresholds based on our expectations is both completely unexpected... and incredibly exciting,” study leader Greg Scherrer of the University of North Carolina said in a statement.
The pathway contains “an extraordinary abundance” of proteins called opioid receptors that play a role in pain control, Scherrer said.
Blocking the pathway interrupted the placebo effect, and activating the pathway caused pain relief even in animals that had not been trained to expect it, he added.
“Our results open the possibility of activating this pathway through other therapeutic means, such as drugs or neurostimulation methods to treat pain,” Scherrer said.
Existing drugs might curb breast tumor growth
Lab experiments on tissue samples from more than 1,500 patients suggest drugs from a class known as sodium channel blockers might help keep breast cancer at bay during the interval between diagnosis and surgery, researchers said.
The drugs have been shown in earlier test tube experiments to keep breast cancers from growing, but how they achieve that effect has not been clear.
By blocking sodium from entering the cancer cells, the drugs cut off a process that enables the cells to move out of the tumor, the researchers found.
When sodium enters the cell, the cell pumps out lactic acid, causing the local area to become more acidic. That increases the activities of enzymes that digest the material that fills the spaces between cells, freeing up room for cancer cells to spread and move out of the tumor, the researchers reported on Thursday in Oncogene.
They also found that human breast cancer tumors with more channels for sodium entry were more likely to metastasize, or spread.
The drugs still need to be tested in clinical trials to see whether targeting sodium channels in breast cancer tumors would be effective in patients.
The drugs are already used to treat conditions such as epilepsy, nerve pain, and heart rhythm disturbances, “so there is a possibility that a drug which already has a good safety profile could be repurposed for breast cancer patients on the waiting list for surgery,” study leader Will Brackenbury from the University of York in the UK said in a statement.
Commercially available sodium blockers include Tegretol (carbamazepine) from Novartis NOVN.S and Dilantin (phenytoin) from Viatris VTRS.O.
Proteins help colorectal cancer cells colonize the liver
Researchers have discovered how colorectal cancer cells manage to attach themselves so effectively to liver cells, according to a report published on Wednesday in Nature.
When colorectal cancers spread to other organs, the liver is usually the first target. Liver metastases affect up to 60% of colorectal cancer patients and are often fatal, earlier studies have shown.
In lab experiments, investigators found that proteins on the surfaces of the colorectal cancer cells and the liver cells bind together in a way that changes the cancer cells and allows them to colonize in the liver.
More specifically, when liver cells traveling in the bloodstream have a protein called Plexin-B2 and the colorectal cancer cells have proteins from the semaphorin family, the colorectal cancer cells can attach themselves to the liver cells.
Further tests have shown that plexin also encourages the formation of metastases in melanoma and pancreatic cancer, the researchers said.
If new treatments can be developed to inhibit the crucial interaction between plexin and semaphorin, it may be possible to prevent these cancers from establishing new tumors, the researchers said in a statement.
Reporting by Nancy Lapid; Editing by Bill Berkrot
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
